OncoSec (ONCS)- Innovative biotech to consider in addition to CLSN.
Key milestones that OncoSec looks forward to accomplishing for 2013 include:
Present interim response data from OncoSec's Phase II melanoma trial along with long-term progression-free survival (PFS) data from its previous Phase I melanoma program
Present final data from OncoSec's Phase II melanoma trial and Merkel cell carcinoma trial
Conduct an end-of-Phase II meeting with the FDA for OncoSec's melanoma and Merkel cell carcinoma program
Present interim data from OncoSec's Phase II cutaneous T-cell lymphoma program
Plan to launch a pivotal Merkel cell carcinoma program
Plan to launch a Phase IIB metastatic melanoma program
OncoSec also reviewed the significant achievements of the company during the past year.
2012: Initiated Three Phase II trials with Patients Now Enrolling in Eight Centers of Excellence Across North America
2012: Presented Positive Interim Data
2012: Secured New Patents, Certification and In-licensing